Lipid formulations of amphotericin B.
The incidence of systemic fungal infections, especially in immunocompromised patients, has continued to increase during the past few decades. Treatment with conventional amphotericin B has been the standard care for the majority of patients with invasive fungal infections, despite its associated toxicity. Three lipid formulations of amphotericin B have now been approved for use in the United States. The pharmacology, pharmacokinetics, clinical experience, toxicity, dosing strategies, and cost of these three preparations--amphotericin B lipid complex, amphotericin B colloidal dispersion, and liposomal amphotericin B--were reviewed in detail in this chapter. The clinical data indicate that lipid formulations of amphotericin B represent an important therapeutic modality in the management of invasive fungal infections.
Dix
S P
SP
Saint Luke's Hospital of Kansas City, Missouri, USA.
Andriole
V T
VT
D000666:Amphotericin B / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics / Q000493:pharmacokinetics; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics / Q000493:pharmacokinetics; D003365:Costs and Cost Analysis; D017850:Economics, Pharmaceutical; D005335:Fever of Unknown Origin / Q000188:drug therapy; D006801:Humans; D016867:Immunocompromised Host; D008081:Liposomes / Q000191:economics; D009181:Mycoses / Q000188:drug therapy*
D000935:Antifungal Agents; D008081:Liposomes; D000666:Amphotericin B